{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:18:00Z","timestamp":1765887480016},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T00:00:00Z","timestamp":1363737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40261-013-0068-y","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T09:18:09Z","timestamp":1363684689000},"page":"351-357","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers"],"prefix":"10.1007","volume":"33","author":[{"given":"Sreeraj","family":"Macha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Pinnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,20]]},"reference":[{"key":"68_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","volume":"378","author":"G Danaei","year":"2011","unstructured":"Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7\u00a0million participants. Lancet. 2011;378:31\u201340.","journal-title":"Lancet"},{"key":"68_CR2","unstructured":"Centers for Disease Control and Prevention. Diabetes and women\u2019s health across the life stages: a public health perspective. Centers for disease control and prevention. 2001. Available from: http:\/\/www.cdc.gov\/diabetes\/pubs\/women\/index.htm . Accessed 1 Nov 2012."},{"key":"68_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","volume":"52","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17\u201330.","journal-title":"Diabetologia"},{"key":"68_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136\u201342.","journal-title":"Diabet Med"},{"key":"68_CR5","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427\u201334.","journal-title":"Diabetes"},{"key":"68_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA Defronzo","year":"2012","unstructured":"Defronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5\u201314.","journal-title":"Diabetes Obes Metab"},{"key":"68_CR7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"68_CR8","first-page":"A172 (629-P)","volume":"59","author":"T Heise","year":"2010","unstructured":"Heise T, Seewaldt-Becker E, Macha S, et al. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl 1):A172 (629-P).","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"68_CR9","first-page":"A156 (571-P)","volume":"59","author":"L Seman","year":"2010","unstructured":"Seman L, Macha S, Jones P, et al. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl 1):A156 (571-P).","journal-title":"Diabetes"},{"key":"68_CR10","first-page":"A155 (569-P)","volume":"59","author":"A Port","year":"2010","unstructured":"Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), in healthy volunteers. Diabetes. 2010;59:A155 (569-P).","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"68_CR11","first-page":"S351 (877)","volume":"53","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Seman LJ, Seewaldt-Becker E, et al. The potent and highly selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(Suppl 1):S351 (877).","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"68_CR12","first-page":"A271 (989-P)","volume":"60","author":"J Rosenstock","year":"2011","unstructured":"Rosenstock J, Jelaska A, Seman L, et al. Efficacy and safety of BI 10773, a new sodium glucose cotransporter (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60(Suppl 1):A271 (989-P).","journal-title":"Diabetes"},{"key":"68_CR13","unstructured":"Bayer plc. Summary of product characteristics for microgynon. Bayer plc. 2011. Available from: http:\/\/www.medicines.org.uk\/EMC\/medicine\/1827\/SPC\/Microgynon+30\/ . Accessed 1 Nov 2012."},{"key":"68_CR14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1528-1157.1999.tb00779.x","volume":"40","author":"C Fattore","year":"1999","unstructured":"Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783\u20137.","journal-title":"Epilepsia"},{"key":"68_CR15","unstructured":"Duramed Pharmaceuticals Ltd. Prescribing information for plan B one step (levonorgestrel). Duramed Pharmaceuticals Ltd. 2012. Available from: http:\/\/www.planbonestep.com\/pdf\/PlanBOneStepFullProductInformation.pdf . Accessed 1 Nov 2012."},{"key":"68_CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2125.2008.03132.x","volume":"65","author":"S Abel","year":"2008","unstructured":"Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine\/zidovudine, and ethinylestradiol\/levonorgestrel in healthy volunteers. Br J Clin Pharmacol. 2008;65:19\u201326.","journal-title":"Br J Clin Pharmacol"},{"key":"68_CR17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/11590240-000000000-00000","volume":"31","author":"C Friedrich","year":"2011","unstructured":"Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. Clin Drug Investig. 2011;31:643\u201353.","journal-title":"Clin Drug Investig"},{"key":"68_CR18","doi-asserted-by":"crossref","unstructured":"Macha S, Rose P, Mattheus M et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter-2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2012; (Epub 2012 Oct 24).","DOI":"10.1111\/dom.12028"},{"key":"68_CR19","unstructured":"Boehringer Ingelheim. Data on file. 2012."},{"key":"68_CR20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1124\/dmd.104.000182","volume":"32","author":"B Wang","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17-alpha-ethinylestradiol. Drug Metab Dispos. 2004;32:1209\u201312.","journal-title":"Drug Metab Dispos"},{"key":"68_CR21","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1345\/aph.1M382","volume":"43","author":"M Zingone","year":"2009","unstructured":"Zingone M, Guirguis A, Airee A, et al. Probable drug interaction between warfarin and hormonal contraceptives. Ann Pharmacother. 2009;43:2096\u2013112.","journal-title":"Ann Pharmacother"},{"key":"68_CR22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.1365-2125.2003.01868.x","volume":"56","author":"S Palovaara","year":"2003","unstructured":"Palovaara S, Tybring G, Laine K. The effect of ethinylestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003;56:232\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"68_CR23","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1046\/j.1365-2125.2000.00153.x","volume":"49","author":"GJ Muirhead","year":"2000","unstructured":"Muirhead GJ, Harness J, Holt PR, et al. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol. 2000;49(Suppl 1):49S\u201356S.","journal-title":"Br J Clin Pharmacol"},{"key":"68_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","volume":"46","author":"H Zhang","year":"2007","unstructured":"Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46:133\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"68_CR25","first-page":"181","volume":"1","author":"S Macha","year":"2012","unstructured":"Macha S, Lang B, Pinnetti S, et al. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers. Clin Pharmacol Drug Dev. 2012;1:181.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0068-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0068-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0068-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T20:43:17Z","timestamp":1644612197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0068-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,20]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0068-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,20]]}}}